Evidence map›Paper›PMID 20879789›Full record

ArticleBiochemistry2010

Streptococcal serum opacity factor increases the rate of hepatocyte uptake of human plasma high-density lipoprotein cholesterol.

Baiba K Gillard, Corina Rosales, Biju K Pillai, Hu Yu Lin, Harry S Courtney, Henry J Pownall

Abstract read
In one paragraph

Article in Biochemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. High Free Cholesterol Bioavailability Drives the Tissue Pathologies in Scarb1Arteriosclerosis, thrombosis, and vascular biology · 2021
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Baiba K GillardSection of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, United States. baibag@bcm.tmc.edu
Corina Rosales
Biju K Pillai
Hu Yu Lin
Harry S Courtney
Henry J Pownall
Baylor College of Medicine · USUniversity of Tennessee Health Science Center · US

Funding

Therapeutic Approaches to Dysregulated HDL MetabolismR01HL056865 · NHLBI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI POWNALL, HENRY J. · 1997 to 2015
$5.2M
ENZYMIC REACTIONS OF MODEL PLASMA LIPOPROTEINSR01HL030914 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI POWNALL, HENRY J. · 1985 to 2010
$2.2M
NHLBI NIH HHS HL-30914NHLBI NIH HHS HL-56865NHLBI NIH HHS R01 HL030914NHLBI NIH HHS R01 HL056865
6 · The paper itself

Abstract

Serum opacity factor (SOF), a virulence determinant of Streptococcus pyogenes, converts plasma high-density lipoproteins (HDL) to three distinct species: lipid-free apolipoprotein (apo) A-I, neo HDL, a small discoidal HDL-like particle, and a large cholesteryl ester-rich microemulsion (CERM) that contains the cholesterol esters (CE) of up to ∼400000 HDL particles and apo E as its major protein. Similar SOF reaction products are obtained with HDL, total plasma lipoproteins, and whole plasma. We hypothesized that hepatic uptake of CERM-CE via multiple apo E-dependent receptors would be faster than that of HDL-CE. We tested our hypothesis using human hepatoma cells and lipoprotein receptor-specific Chinese hamster ovary (CHO) cells. The uptake of [(3)H]CE by HepG2 and Huh7 cells from HDL after SOF treatment, which transfers >90% of HDL-CE to CERM, was 2.4 and 4.5 times faster, respectively, than from control HDL. CERM-[(3)H]CE uptake was inhibited by LDL and HDL, suggestive of uptake by both the LDL receptor (LDL-R) and scavenger receptor class B type I (SR-BI). Studies in CHO cells specifically expressing LDL-R and SR-BI confirmed CERM-[(3)H]CE uptake by both receptors. RAP and heparin inhibit CERM-[(3)H]CE but not HDL-[(3)H]CE uptake, thereby implicating LRP-1 and cell surface proteoglycans in this process. These data demonstrate that SOF treatment of HDL increases the rate of CE uptake via multiple hepatic apo E receptors. In so doing, SOF might increase the level of hepatic disposal of plasma cholesterol in a way that is therapeutically useful.

Indexed as

AnimalsBoron CompoundsCell Culture TechniquesCHO CellsCholesterol EstersCholesterol, HDLCricetinaeCricetulusHepatocytesHumansKineticsLiverMicroscopy, ConfocalPeptide HydrolasesStreptococcus pyogenesVirulenceBoron CompoundsCholesterol EstersCholesterol, HDLcholesteryl 4,4-difluoro-5,7-dimethyl-4-bora-3,4-diaza-3-indacenedodecanoateopacity factorPeptide Hydrolases

Identifiers

PMID20879789
PMCPMC2982792
OpenAlexW2076745890

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.